[Intraamniotic surfactant supply as RDS prevention]

Jacek Lisawa1, Dariusz Pietrasik, Jerzy Zwoliński

  • 1Klinika Połoznictwa i Ginekologii IMD, Instytut Matki i Dziecka w Warszawie.

Medycyna Wieku Rozwojowego
|November 13, 2004
PubMed

Insights

Antenatal steroids and postnatal surfactant are established treatments for respiratory distress syndrome (RDS). Intra-amniotic surfactant, administered before birth, shows promise for RDS prevention with no observed complications in this preliminary study.

Area of Science:

  • Neonatal Medicine
  • Pulmonology
  • Obstetrics

Context:

  • Respiratory Distress Syndrome (RDS) is a significant cause of neonatal morbidity and mortality.
  • Antenatal corticosteroids and postnatal surfactant therapy are current standards of care but have limitations.
  • Novel strategies for RDS prevention are actively being researched.

Purpose:

  • To evaluate the safety and efficacy of intra-amniotic surfactant administration for preventing RDS.
  • To assess the feasibility of delivering surfactant directly into the amniotic cavity prior to delivery.
  • To investigate the role of provoking fetal breathing movements before surfactant instillation.

Summary:

  • Natural surfactant was administered intra-amniotically to 15 pregnant women between 24-32 weeks gestation, prior to scheduled delivery.
  • Ultrasound guidance was used for surfactant instillation near the fetal airway; Aminophylline was given to stimulate fetal breathing.
  • No procedural complications were noted, and newborns showed reduced severe asphyxia and no need for postpartum surfactant therapy.

Impact:

  • Intra-amniotic surfactant instillation appears to be a safe and potentially effective method for RDS prevention.
  • Preliminary results suggest a favorable outcome for newborns, with a high survival rate and reduced need for mechanical ventilation.
  • Further research with larger cohorts is warranted to confirm these encouraging findings and establish clinical utility.